June 17, 2020 10:30 AM EDT

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox

John Carroll

Editor & Founder

We already knew from BioMarin’s statement a few days ago that their gene therapy for hemophilia A continued to protect patients against the bleeding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Bio­Marin spells out a trou­bling slide in Fac­tor VI­II lev­els for its big block­buster con­tender val­rox

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox